Quantum Biopharma Ltd. Subordinate Voting Shares Class B QNTM 深 滬
等待開盤 04-06 09:30:00 美东时间
3.98
-0.430
-9.75%
華盛通- 最 高4.5999
- 今 開4.45
- 成交量 44.37万股
- 最 低 3.87
- 昨 收 4.41
- 總市值 2320.05万
- 52周最高 38.25
- 市盈率 靜 --
- 換手率 7.61%
- 52周最低 2.07
- 委 比 -14.64%
- 總股本 582.93万
- 歷史最高 909.5234
- 量 比 0.49
- 振 幅 16.55%
- 歷史最低 2.07
- 每 手 1
- 風險率 6.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Quantum BioPharma Submits IND Application To FDA For Lucid-21-302, Its New Drug Candidate For Treatment Of Multiple Sclerosis
Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today
04-01 20:09
Quantum BioPharma Q4 EPS $(0.71) Beats $(0.93) Estimate
Quantum BioPharma (NASDAQ:QNTM) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.93) by 23.66 percent. This is a 65.53 percent increase over losses of $(2.06) per share from
03-27 05:58
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers ENvue Medical (NASDAQ:FEED) shares increased by 59.4% to $2.28 during T...
03-25 01:05
Quantum BioPharma Publishes Data From Clinical Study Of NCT06505239 Of Its Dietary Supplement Product Unbuzzd To Evaluate Impacts Of Unbuzzd On Alcohol Intoxication, Alcohol Metabolism
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions,
03-23 20:28
Reported On March 11: Quantum BioPharma Provides Corporate Update; Announces That Further To Its News Release On March 10, 2026, The Company Has Revised The Terms Of The Debenture Units; Reduce The Conversion Price Per Share To $3.00; Increase The Number Of Warrants Included As Part Of Each Debenture Unit To 333.33; Reduce The Exercise Price Per Warrant Share To $3.75
https://www.globenewswire.com/news-release/2026/03/11/3254229/0/en/Quantum-BioPharma-Provides-Corporate-Update.html
03-12 22:19
Quantum BioPharma Shareholder Sues Canadian Imperial Bank Of Commerce, Royal Bank Of Canada, RBC Capital Markets Over Alleged Stock Manipulation
Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"),understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma
2025-12-22 22:06
Quantum BioPharma To Broadcast Three-Part Series About Allegations Of Stock Market Manipulation Against Company
Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma"), is pleased to announce that national television network CTV News' flagship investigative program W5 will air, starting today, a
2025-11-26 05:02
Quantum BioPharma Q3 EPS $(1.25) Misses $(0.08) Estimate
Quantum BioPharma (NASDAQ:QNTM) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(0.08) by 1462.5 percent. This is a 71.4 percent increase over losses of $(4.37) per share
2025-11-07 21:47
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication
Quantum BioPharma’s licensee, Unbuzzd Wellness, announces a Reg D 506(c) offering targeting $5 million to expand distribution and retail sales of its hangover-relief beverage, unbuzzd. An investor webinar on Oct 30, 2025, will discuss the investment opportunity, leadership, and growth strategy. Unbuzzd, scientifically proven to accelerate alcohol metabolism and reduce hangover symptoms, has gained traction due to its innovation and market relevan...
2025-10-23 12:15
Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend
Quantum BioPharma Ltd. announced the expiration of 53,147 warrants issued to hedge funds and investment funds as part of a 2020 financing. The company reaffirmed October 27, 2025, as the record date for distributing Contingent Value Rights (CVRs) to Class B Subordinate Voting Shareholders. Each CVR entitles holders to a portion of net proceeds from ongoing litigation against financial institutions, seeking over $700 million in damages for alleged...
2025-10-20 12:30
